The Eternaline ingredient, which is based on advances in regenerative medicine on bone tissue, aims at stimulating the synthesis of periostin; which is a regenerative protein in the extracellular cutaneous matrix that is strongly involved in maintaining homeostasis and tissue architecture.
According to Silab, the active regenerates the structure of the collagen fibres damaged by ageing, and optimizes the function of the matrix network and reinforces the mechanical properties of the dermis.
The product was tested in vivo, and found to consolidate the dermal tissue, while reducing general sagging at the base of the face.
Eternaline is rich in oligosaccharides of common shrubby everlasting, Helichrysum stoechas, which is sourced from the Southern Atlantic coast of France in a controlled, traceable supply chain with the local producers.
Silab says that the ingredient is aimed at anti-ageing regenerative day/night skin care products and is compliant with Europe, USA, Japan, and China cosmetic regulations.
The active was tested in a number of studies to prove its efficacy, beginning with an ex vivo in aged skin which showed that it restores the synthesis of periostin when used in a cream containing 1% active.
Eternaline was also tested in vitro by light microscopy and transmission electron microscopy, at 0.25% on fibroblasts obtained from aged donors, and shown to significantly restore the production of the collagen I network by 361%.
An in vivo study by high frequency ultrasonography also demonstrated that the active reinforces the dermal structure; whilst after 42 days of twice daily applications and in comparison to the placebo, it also significantly reduced sagging at the base of the face in 77% of the volunteers.
According to Silab, a subjective evaluation of its benefits, carried out by the same panelists, showed that 91% of the volunteers reported that their skin was firmer.